Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

Leaked data show Gilead’s remdesivir allows severe COVID-19 patients to be discharged after six days

April 17, 2020
Medical Communications, Research and Development COVID-19, Gilead, coronavirus, remdesivir

The clinical benefit of Gilead’s promising antiviral therapy Remdesivir has been touted in the treatment of severe cases of COVID-19 …

News
gilead-sciences

Gilead halts COVID-19 remdesivir trial due to enrolment issues, efficacy of the drug uncertain

April 16, 2020
Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir

A clinical trial in China investigating Gilead’s antiviral therapy remdesivir as a potential treatment for COVID-19 has been placed on …

News
bristolll

Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute

April 14, 2020
Manufacturing and Production Bristol-Myers Squibb, Gilead, bristol myers squibb

A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company’s …

News
gilead-sciences

Gilead’s promising COVID-19 drug remdesivir shows benefit in 68% of hospitalised patients

April 14, 2020
Manufacturing and Production, Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir

Gilead has provided an update on its ongoing efforts against the novel coronavirus, revealing data from a cohort analysis of …

News
partnership

Second Genome to help drive development of Gilead therapies in potential $1.5bn deal

April 8, 2020
Research and Development Gilead, Second Genome, pharma

Gilead and microbiome science specialist Second Genome have announced they are to partner up to advance a selection of the …

News
flag_of_world_health_organization_at_un_city

WHO launches “historic” multinational study to investigate most promising COVID-19 therapies

March 30, 2020
Research and Development, Sales and Marketing COVID-19, Gilead, coronavirus, pharma, remdesivir

The World Health Organization continues to push forward in the global fight against the novel coronavirus, and has announced the …

News
000000000

Gilead asks FDA to rescind its Orphan Drug status for potential coronavirus treatment following criticism

March 26, 2020
Business Services China, Gilead, Wuhan Coronavirus, china coronavirus, coronavirus

Gilead Sciences has submitted a request for the FDA to rescind its offer of Orphan Drug designation for remdesivir in …

News
shutter

COVID-19: Gilead freezes compassionate access to remdesivir due to “overwhelming demand”, BMS and Lilly delay new study launches

March 24, 2020
Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, Eli Lilly, Gilead, Roche, cornavirus, pharma

As national governments continue to ramp up measures to contain the ongoing COVID-19 coronavirus outbreak, so too are pharma and …

News
gilead-sciences

FDA greenlights Gilead’s Epclusa in hepatitis C patients over six years old

March 20, 2020
Medical Communications, Research and Development Epclusa, Gilead, pharma

Gilead’s Epclusa (sofosbuvir and velpatasvir) has been awarded new marketing approval from the FDA in the treatment of hepatitis C …

News
gilead_hq_at_stockley_park_london_2

Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal

March 3, 2020
Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma

Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …

News
shutterstock

First US coronavirus trial launched into Gilead’s remdesivir

February 26, 2020
Research and Development FDA, Gilead, US, coronavirus, pharma

The first US clinical trial investigating a treatment for the COVID-19 coronavirus has been launched by the US National Institute …

News
m-mansuri_370x250px

Sanofi’s head of strategy and business development to retire amid company review

November 25, 2019
Sales and Marketing Bristol Meyers, Gilead, Sanofi, Shell

One of Sanofi’s most senior strategy bosses is set to retire at the end of the month. Muzammil Mansuri, Executive …

News
gilead-sciences

Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome

October 28, 2019
Research and Development, Sales and Marketing Gilead, Lupus, filgotinib, pharma

Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment of rheumatoid arthritis has been …

News
5204602349_c87b204860_z

FDA warns three Hepatitis C drugs may worsen liver function in some rare cases

August 29, 2019
Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health

The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …

News
gilead-sciences

Gilead challenges Government over patents on preventative HIV drug Truvada

August 22, 2019
Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents

Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025